Investors ~ News
|Press Release Navigation|
|<<< Previous||Headlines||Next >>>|
FOR: INNOVOTECH INC.
InnovoSCEPT Antimicrobial Susceptibility Tests Approved for Sale in Canada
APR 23, 2012 - 08:00 ET
EDMONTON, ALBERTA--(Marketwire - April 23, 2012) - Innovotech Inc. (TSX VENTURE:IOT), today announced that Health Canada has approved two (2) InnovoSCEPT antimicrobial susceptibility tests for sale in Canada, an important step in the improved treatment of chronic infections.
The InnovoSCEPT tests join the previously approved, breakthrough product bioFILM PA™ to provide a range of tests for virtually all chronic bacterial infections that plague human health. "These biofilm tests give doctors information about the most effective antibiotic treatment to use against a patient's particular bacterial infection." states Ken Boutilier, President of Innovotech. "Chronic infections, or those infections that resist eradication or keep returning, are usually biofilm infections. Before the advent of Innovotech's tests doctors had to rely on intuition, experience and educated guesses to prescribe antibiotics for chronic infections. Available tests only tested for effectiveness against easy to treat, free floating bacteria rather than the hard to eradicate colonies or biofilms that bacteria build to defend themselves." InnovoSCEPT tests antibiotics against the particular biofilm that is infecting a patient, so the chances that a recommended treatment will work are greatly enhanced.
Antibiotic treatments that do not work cause patients to suffer more, allow the bacteria to build resistance, and are expensive for the health care system. The InnovoSCEPT tests have the potential to recommend antibiotics that work the first time, to improve quality of life for the patient, to shorten hospital stays, to save the health systems money, and to lengthen the time it takes for bacteria to develop resistance to antibiotics.
It is estimated that over 17 million patients in the United States suffer from chronic biofilm infections at a cost to the health care system of over $94 billion. Of these patients 550,000 will die from these infections equal to the number of patients who die from cancer.
These 2 new products join the growing family of InnovoSCEPT tests for human health approved in Canada and Israel and marketed by LevPharm in Israel; and InnovoSCEPT tests for veterinary health marketed worldwide by Spectrum Labs.
About Innovotech Inc.
Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.
Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including commercially available products in three market segments; the MBEC Assay™, bioFILM PA™, InnovoSCEPT-Human and InnovoSCEPT-Veterinary tests. The MBEC Assay™ is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA™ and InnovoSCEPT-Human are the first diagnostic tests to assist physicians in the selection of the most effective antibiotic treatment for patients with biofilm-based chronic infections, while the InnovoSCEPT veterinary tests are designed to determine the most effective antibiotic treatment for chronic infections in both large and small animals.
Innovotech also has three products in advanced stages of development; Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections, AgreGuard™ is a unique antimicrobial for coating medical devices such as catheters, and Sani-Lux™ is a light-activated, natural hard surface sanitizer.
Connect with us:
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.
President and CEO
(780) 448-0585 ext. 221
(780) 424-0941 (FAX)